Skip to content
lifestyle.getpetsavvy.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Novo Nordisk
Novo’s Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes
October 23, 2026
Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD
September 29, 2026
Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis
September 17, 2026
Novo Nordisk’s Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
August 11, 2026
Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
July 11, 2026
Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge
July 1, 2026
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
June 26, 2026